ModernGraham Valuation

IDEXX Laboratories,



Company Ticker Date of Analysis



Inc.



Stage 1: Is this company suitable for the Defensive Investor or the Enterprising Investor?

Defensive Investor; must pass 6 out of the following 7 tests.

Defensive Investor; n	nust pass 6 out of the following 7 tests.		
	1. Adequate Size of the Enterprise	Market Cap > \$2Bil	\$19,085,590,100 Pass
	2. Sufficiently Strong Financial Condition	Current Ratio > 2	0.96 Fail
	3. Earnings Stability	Positive EPS for 10 years prior	Pass
	4. Dividend Record	Dividend Payments for 10 years prior	Fail
		Increase of 33% in EPS in past 10	
	5. Earnings Growth	years using 3 year averages at beginning and end	162.85% Pass
	6. Moderate PEmg Ratio	PEmg < 20	73.05 Fail
	7. Moderate Price to Assets	PB Ratio < 2.5 OR PB*PEmg < 50	-398.98 Fail
Enterprising Investor;	must pass 4 out of the following 5 tests, or be	suitable for the Defensive Investor.	
	1. Sufficiently Strong Financial Condition	Current Ratio > 1.5	0.96 Fail
	2. Sufficiently Strong Financial Condition	Debt to NCA < 1.1	-22.45 Fail
	3. Earnings Stability	Positive EPS for 5 years prior	Pass
	4. Dividend Record	Currently Pays Dividend	Fail
	5. Earnings Growth	EPSmg greater than 5 years ago	Pass
		Score	
Suitability			
	Defensive	No	
	Enterprising	No	
Stage 2: Dete	rmination of Intrinsic Value		
U	EPSmg	\$3.01	
	MG Growth Estimate	12.48%	
	MG Value	\$100.64	
	MG Value based on 3% Growth	\$43.62	
	MG Value based on 0% Growth	\$25.57	
	Market Implied Growth Rate	32.27%	
MG Opinion			
	Current Price	\$219.72	
	% of Intrinsic Value	218.32%	
	Opinion	Overvalued	

Stage 3: Information for Further Research

MG Grade

Net Current Asset Value (NCAV)	-\$9.18
Graham Number	\$0.00
PEmg	73.05
Current Ratio	0.96
PB Ratio	-398.98
Current Dividend	\$0.00
Dividend Yield	0.00%
Number of Consecutive Years of Dividend	
Growth	0


F


Useful Links:

ModernGraham tagged articles Google Finance Yahoo Finance GuruFocus

Morningstar MSN Money Seeking Alpha SEC Filings

EPS History		EPSmg History	
Next Fiscal Year			
Estimate	\$4.03	Next Fiscal Year Estimate	\$3.01
Dec2017	\$2.94	Dec2017	\$2.40
Dec2016	\$2.44	Dec2016	\$2.06
Dec2015	\$2.05	Dec2015	\$1.8
Dec2014	\$1.79	Dec2014	\$1.64
Dec2013	\$1.74	Dec2013	\$1.5
Dec2012	\$1.59	Dec2012	\$1.33
Dec2011	\$1.39	Dec2011	\$1.1
Dec2010	\$1.19	Dec2010	\$0.9
Dec2009	\$1.01	Dec2009	\$0.8
Dec2008	\$0.94	Dec2008	\$0.7
Dec2007	\$0.73	Dec2007	\$0.6
Dec2006	\$0.71	Dec2006	\$0.5
Dec2005	\$0.58	Dec2005	\$0.4
Dec2004	\$0.55	Dec2004	\$0.4
Dec2003	\$0.40	Dec2003	\$0.3
Dec2002	\$0.33	Dec2002	\$0.2
Dec2001	\$0.27	Balance Sheet Information	3/1/201
Dec2000	\$0.26	Total Current Assets	\$701,707,000
Dec1999	\$0.21	Total Current Liabilities	\$728,838,00
Dec1998	-\$0.10	Long-Term Debt	\$609,005,00
		Total Assets	\$1,469,492,00
		Intangible Assets	\$242,915,00
		Total Liabilities	\$1,518,474,00
		Shares Outstanding (Diluted Average)	88,944,000





Disclaimer:

This valuation is not investment advice. Anyone who is considering making an investment decision should speak to a registered investment advisor. The author did not hold a position in any company mentioned in this article at the time of publication and had no intention of changing those holdings within the next 72 hours.

Recommended Reading:

Other ModernGraham posts about the company IDEXX Laboratories Inc Valuation – Initial Coverage \$IDXX

Other ModernGraham posts about related companies Mettler-Toledo International Inc Valuation – June 2018 \$MTD Envision Healthcare Corp Valuation – June 2018 \$EVHC DaVita Inc Valuation – June 2018 \$DVA Danaher Corp Valuation – May 2018 \$DHR Agilent Technologies Inc Valuation – May 2018 \$A Cooper Companies Inc Valuation – May 2018 \$COO Edwards Lifesciences Corp Valuation – May 2018 \$EW Baxter International Inc Valuation – May 2018 \$BAX Boston Scientific Corp Valuation – May 2018 \$BSX Centene Corp Valuation – May 2018 \$CNC